Castle Biosciences, Inc. CSTL is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is...
Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by investor enthusiasm about the company’s encouraging preliminary sales numbers...
Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...
The primary purpose of a business is to generate profits that can be reinvested in expansion or utilized for rewarding shareholders. Net profit margin is an effective tool to measure the profits reaped...
Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive...